Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.
A recent clinical trial achieved its primary visual acuity endpoints in both the US and EU/UK, demonstrating statistically significant near vision improvements over 8 hours.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.